This study has proven through phase II clinical studies that retarglutide, as the only three-hormone receptor agonist at present, can reduce body weight by up to 24.2%, almost achieving the effect of bariatric surgery.

Generally speaking, glucagon-like peptide-1 receptor agonist (GLP-1A) type of weight-loss drugs, represented by liraglutide injection and semaglutide injection, have improved results during one-year follow-up. It can reduce body weight by about 8% or 17% in the first stage, and the current weight loss effect of bariatric surgery (gastric volume reduction surgery) is also about 30%. Retatrutide (LY3437943) recently launched by Eli Lilly and Company is a joint agonist of three hormone receptors, namely glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulin release. Co-agonist of polypeptide receptor (GIP) and glucagon receptor (GCG). Could the drug lead to more significant weight loss? Recently, the NEJM journal published the results of the Phase II clinical study of Retatrutide.

In this phase 2, randomized controlled, double-blind clinical trial, the researchers enrolled patients with a body mass index (BMI) >= 30 or a BMI >= 27 plus at least one obesity-related disease/abnormality. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive weekly subcutaneous injections of retalglutide (1 mg, 4 mg [initial 2 mg], 4 mg [initial 4 mg], 8 mg [initial 2 mg], 8 mg [initially 4 mg], or 12 mg [initially 2 mg]) or placebo for 48 weeks. The primary endpoint was the percent change from baseline in body weight at 24 weeks. Secondary endpoints included percent weight change from baseline to 48 weeks with a weight loss of 5% or more, 10% or more, or 15% or more. Drug safety indicators were also assessed.

The results of the study showed that among the 338 adults recruited, 51.8% were male. The percent change in body weight at 24 weeks was -7.2% in the 1 mg group, -12.9% in the 4 mg group, -17.3% in the 8 mg group, -17.5% in the 12 mg group, and -1.6% in the placebo group. At 48 weeks of follow-up, percent body weight changes in the retarglutide group were -8.7% in the 1 mg group, -17.1% in the combined 4 mg group, -22.8% in the combined 8 mg group, and -24.2% in the 12 mg group, compared with placebo Group is -2.1%. At 48 weeks, the proportion of patients with weight loss of more than 5%, more than 10%, and more than 15% in the treatment group receiving 4 mg retarglutide were 92%, 75%, and 60% respectively; in the group receiving 8 mg retarglutide, 100%, 91% and 75% respectively in the treatment group; 100%, 93% and 83% respectively in the treatment group receiving 12mg retarglutide; 27%, 9% and 2% respectively in the placebo treatment group. %. The most common adverse reactions in the retalglutide treatment group were gastrointestinal symptoms. The occurrence of these adverse reactions was dose-related, and the severity was mostly mild to moderate. In the treatment groups starting with low doses such as 2 mg and 4 mg, Medium less. Heart rate increased in a dose-dependent manner and peaked at 24 weeks before declining.

This study has proven through phase II clinical studies that retarglutide, as the only three-hormone receptor agonist currently, can reduce body weight by up to 24.2%, almost achieving the effect of bariatric surgery. Moreover, relatively speaking, weight loss surgery also needs to consider issues such as psychological stress, postoperative recovery, and possible postoperative rebound. Recently, these weight-loss miracle drugs have been popping up in endlessly, from powerful injections to oral alternatives. I believe that with these weapons, humans in the future will be very slim, but diet and exercise may still be powerful tools to maintain weight loss. Weight-loss drugs and surgery can help you "lose weight." Exercise and diet can ensure that you continue to "lose weight."